8-K: Assembly Biosciences Reports Positive Phase 1b Results for ABI-4334 in Chronic Hepatitis B, Triggering Gilead Option

Assembly Biosciences announced positive topline results from its Phase 1b clinical trial of ABI-4334 for chronic hepatitis B, which triggers an opt-in point for its collaboration with Gilead Sciences.

Summary

• Assembly Biosciences reported positive topline efficacy, safety, and pharmacokinetic (PK) results from a Phase 1b study evaluating ABI-4334, an investigational next-generation capsid assembly modulator (CAM), in participants with chronic hepatitis B virus (HBV) infection.
• The 400 mg oral daily dose cohort demonstrated potent antiviral activity over the 28-day treatment period, similar to that previously reported for the 150 mg dose cohort.
• Mean plasma HBV DNA reductions were 3.2 log10 IU/mL over 28 days of treatment for the 400 mg cohort and 2.9 log10 IU/mL for the 150 mg cohort.
• In the subset of participants with detectable HBV RNA at baseline, mean declines of 2.5 log10 U/mL (150 mg cohort) and 2.3 log10 U/mL (400 mg cohort) were observed.
• ABI-4334 exhibited a favorable safety and tolerability profile across both cohorts, with no serious adverse events or adverse events leading to study drug discontinuation.
• PK data supports once-daily oral dosing and achieved exposure levels at greater multiples of the target exposure anticipated to fully engage both inhibition of viral replication and inhibition of cccDNA formation.
• The completion of this trial triggers an opt-in point under the collaboration agreement with Gilead Sciences, Inc., following the delivery and review of the Phase 1b option data package.

Sentiment

Score: 8

Explanation: The document reports positive topline clinical trial results for a key investigational drug, demonstrating favorable safety, tolerability, and potent antiviral activity, which triggers a significant collaboration option with Gilead Sciences. This indicates strong progress in their drug development pipeline and potential for future partnership and funding.

Positives

• Positive topline efficacy, safety, and pharmacokinetic (PK) results from the Phase 1b study of ABI-4334.
• Favorable safety and tolerability profile observed across 150 mg and 400 mg cohorts, with no serious adverse events or study drug discontinuations.
• Potent antiviral activity observed in both 150 mg and 400 mg cohorts, with mean plasma HBV DNA reductions of 2.9 and 3.2 log10 IU/mL, respectively, over 28 days.
• Pharmacokinetics support once-daily oral dosing and achieved exposure levels multiple times higher than anticipated for potent antiviral activity and inhibition of cccDNA formation.
• The trial completion triggers an opt-in point for Gilead Sciences, Inc. under their collaboration agreement, indicating potential for further development and commercialization by a major pharmaceutical partner.
• ABI-4334 achieved the company's target clinical profile with strong antiviral activity.

Negatives

• Limited changes in viral antigens were observed, though this was anticipated given the 28-day treatment period.
• Two grade three treatment-emergent lab abnormalities were observed (one alanine aminotransferase (ALT) elevation in a participant receiving 150 mg ABI-4334, and one total bilirubin elevation in a placebo recipient), though both resolved with continued dosing.

Risks

• Assembly Bio's ability to maintain financial resources necessary to continue its research activities, clinical studies, and other business operations.
• Assembly Bio's ability to realize the potential benefits of its collaboration with Gilead Sciences, Inc. (Gilead), including all financial aspects of the collaboration and equity investments.
• Assembly Bio's ability to initiate and complete clinical studies involving its therapeutic product candidates, including studies contemplated by Assembly Bio's collaboration with Gilead, in the currently anticipated timeframes or at all.
• Safety and efficacy data from clinical or nonclinical studies may not warrant further development of Assembly Bio's product candidates.
• Clinical and nonclinical data may not differentiate Assembly Bio's product candidates from other companies' candidates.
• Potential effects of changes in government regulation, including as a result of the change in U.S. administration in 2025.
• Results of nonclinical studies may not be representative of disease behavior in a clinical setting and may not be predictive of the outcomes of clinical studies.

Future Outlook

The positive Phase 1b results for ABI-4334 will support discussions on potential next steps with Gilead Sciences as they evaluate their option to the program. The company believes that maximizing direct antiviral activity and inhibition of cccDNA formation will be important components of regimens targeting a cure for chronic HBV infection, likely requiring combination approaches. Assembly Bio expects to submit data from the trial for presentation at future scientific meetings.

Management Comments

• "We are pleased to see that our most potent CAM, ABI-4334, achieved our target clinical profile with strong antiviral activity in both cohorts." Anuj Gaggar, MD, PhD, chief medical officer of Assembly Bio.
• "These data support the ability of ABI-4334 to effectively inhibit viral replication at the lower 150 mg dose, while offering the potential to dose higher for purposes of maximizing inhibition of cccDNA formation." Anuj Gaggar, MD, PhD, chief medical officer of Assembly Bio.
• "We believe that maximizing direct antiviral activity and inhibition of cccDNA formation will be important components of regimens targeting cure of chronic HBV infection, and that achieving cure will likely require combination approaches with additional mechanisms still being explored by the field." Anuj Gaggar, MD, PhD, chief medical officer of Assembly Bio.
• "These results will support discussions on potential next steps for ABI-4334 with our partner Gilead as they evaluate their option to the program." Anuj Gaggar, MD, PhD, chief medical officer of Assembly Bio.

Industry Context

The development of novel therapeutics targeting serious viral diseases like chronic HBV is a key focus in the biotechnology industry. Capsid assembly modulators (CAMs) represent a promising class of antivirals aiming to inhibit viral replication and formation of the viral reservoir (cccDNA), which are considered crucial for achieving a functional cure for HBV. The collaboration with Gilead Sciences, a major player in antiviral drug development, validates the potential of ABI-4334 and positions Assembly Bio within the competitive landscape of HBV cure research, where combination therapies are increasingly seen as the path forward.

Stakeholder Impact

• Shareholders: Positive impact due to successful clinical trial results, potential for Gilead partnership, and advancement of a key pipeline asset, which could increase company valuation.
• Patients with Chronic HBV: Potential for a new, effective, and well-tolerated treatment option, especially as part of future combination therapies aiming for a cure.
• Employees: Positive impact due to successful R&D progress and potential for continued development and commercialization activities.
• Gilead Sciences: Opportunity to exercise an exclusive license for a promising HBV therapeutic, potentially expanding their antiviral portfolio.

Next Steps

• Gilead Sciences, Inc. will review the Phase 1b option data package to evaluate their right to opt in to an exclusive license for further development and commercialization of ABI-4334.
• Assembly Bio expects to submit data from the trial for presentation at future scientific meetings.

Key Dates

Recommendation

Keywords

Hepatitis B, HBV, ABI-4334, Capsid Assembly Modulator, CAM, Clinical Trial, Phase 1b, Antiviral, Gilead Sciences, Biotechnology, Drug Development, Chronic Hepatitis B, cccDNA, Viral Replication